Mithridion

closed

Mithridion develops drugs for central nervous system disorders, with special focus on schizophrenia and Alzheimer's disease.

Launch date

2004

Employees

Market cap

Enterprise valuation

Madison Wisconsin (HQ)

Date	Investors	Amount	Round
Mar 2007	Wisconsin Investment Partners Venture Investors Rosetta Partners Wisconsin Alumni Research Foundation	$2.2m	Series A
Jan 2009	Wisconsin Investment Partners Venture Investors Rocket Ventures	$2.9m	Series B
Jan 2011	Venture Investors Rocket Ventures	$1.3m	Series C
Total Funding		$6.4m

Recent News about Mithridion